Therapy Areas: Cardiovascular
Dr. Reddy's Launches Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the US Market
28 September 2020 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the US Food and Drug Administration (USFDA), the company said.

The Precedex in 0.9% Sodium Chloride Injection brand and generic market had US sales of approximately USD 210m MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy's Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively.

The strength is based on the dexmedetomidine base.

Containers are intended for single-dose only.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

The company's major markets include USA, India, Russia and CIS countries, and Europe.
Login
Username:

Password:


Related Headlines